دورية أكاديمية
Treatment with lorecivivint, a novel, intra-articular CLK/DYRK1A inhibitor that modulates the WNT pathway, led to improved responder outcomes in subjects with knee osteoarthritis: a post HOC analysis of a phase 2b trial
| العنوان: | Treatment with lorecivivint, a novel, intra-articular CLK/DYRK1A inhibitor that modulates the WNT pathway, led to improved responder outcomes in subjects with knee osteoarthritis: a post HOC analysis of a phase 2b trial |
|---|---|
| المؤلفون: | Yazici, Y., Kennedy, S., Swearingen, C.J., Tambiah, J. |
| المصدر: | In Osteoarthritis and Cartilage April 2020 28 Supplement 1:S358-S358 |
| قاعدة البيانات: | ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 10634584 |
|---|---|
| DOI: | 10.1016/j.joca.2020.02.559 |